Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro

Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro

Sitravatinib, also called MGCD516 or MG-516, is a broad-spectrum tyrosine kinase inhibitor (TKI) under phase III clinical evaluation. Herein, we explored the activity of sitravatinib toward multidrug resistance (MDR) by emphasizing its inhibitory effect on ATP-binding cassette super-family G member...

Full description

Bibliographic Details
Main Authors: Yuqi Yang, Ning Ji, Qiu-Xu Teng, Chao-Yun Cai, Jing-Quan Wang, Zhuo-Xun Wu, Zi-Ning Lei, Sabrina Lusvarghi, Suresh V. Ambudkar, Zhe-Sheng Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Oncology
Subjects:
sitravatinib
tyrosine kinase inhibitor
multidrug resistance
ATP-binding cassette (ABC) transporters
ATP-binding cassette super-family G member 2 (ABCG2)
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00700/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00700/full

Similar Items